-
In December, a large number of pharmaceutical companies were fined for announcing that the fine reached hundreds of millions of yuan
Time of Update: 2022-12-30
js?cdnversion='+~(-new Date()/36e5)];With the implementation and advancement of the new version of the Drug Administration Law and the tightening of the supervision of the pharmaceutical industry, a large number of pharmaceutical companies' illegal sales of inferior drugs and illegal operations are being exposed one after another, which continues to wake up the industry.
-
The purchase of 35 Chinese medicine pieces such as American ginseng, bezoar and goji berry leaves was suspended
Time of Update: 2022-12-30
The combing found that the Chinese medicine pieces suspended this time included fried locust rice (flower), yellow lip gum, pearls, wolfberry leaves, lamp charcoal, forest ginseng, red ginseng whiskers, red ginseng reed, American ginseng, Inner Mongolian comfrey, cordyceps, deer antler blood tablets, deer antler powder tablets, deer tendon, sand fried leopard bones, sand fried monkey bones, antelope horn tip powder, etc.
-
The outline of the preparation of the Chinese Pharmacopoeia (2025 edition) has been released!
Time of Update: 2022-12-30
From: National Pharmacopoeia Editor: Crystal On December 19, the Pharmacopoeia Commission released the outline of the Chinese Pharmacopoeia (2025 edition). The Outline points out that by 2025, the pr
-
Strengthen the work related to the transfer and use of preparations prepared by medical institutions for children during the epidemic
Time of Update: 2022-12-30
All provinces, autonomous regions, municipalities directly under the Central Government and the Xinjiang Production and Construction Corps Joint Prevention and Control Mechanism (Leading Group and He
-
The information platform of the non-clinical safety evaluation research institution of drugs was put into operation
Time of Update: 2022-12-30
From the date of issuance of the circular, GLP institutions, relevant provincial drug administrations, and the Food and Drug Inspection and Inspection Center of the State Medical Products Administration (hereinafter referred to as the verification center) shall log in to the GLP institution information platform and promptly fill in GLP institution information, GLP certification status, supervision and inspection results of GLP institutions, investigation and handling of illegal acts, and other information.
-
Since December, many pharmaceutical companies have encountered setbacks in drug research and development
Time of Update: 2022-12-30
js?cdnversion='+~(-new Date()/36e5)];On December 19, AstraZeneca announced that the drug Imfinzi, as a monotherapy for patients with advanced non-small cell lung cancer, failed to achieve its primary goal of improving overall survival compared to platinum-based chemotherapy.
-
Many pharmaceutical companies suspended! All trading was suspended due to abnormal fluctuations in the rise and fall
Time of Update: 2022-12-30
2 million in the same period in 2021; The net loss in the first quarter of 2022 was approximately RMB14.
2 million in the same period in 2021; The net loss in the first quarter of 2022 was approximately RMB14.
-
The double antibody research and development track is hot! Cinda and other nuggets exceed 200 billion market
Time of Update: 2022-12-30
Sales of anti-tumor and immunomodulatory agents in China's three major terminal markets in recent years (: million yuan)Source: Minai Grid Bureau database From the perspective of treatment categories, anti-tumor and immunomodulatory agents are the majority, and a total of 71 drugs are undergoing clinical research; There are 3 sensory system drugs, 2 blood and hematopoietic system drugs, 1 digestive system and metabolic drug, and 1 systemic anti-infective drug, all of which have entered the clinical trial stage.
-
The pharmaceutical's executives have changed! A group of new appointments and a group of resignations
Time of Update: 2022-12-30
Recently, Jiashi Hall issued an announcement on the completion of the election of the board of directors and the board of supervisors and the appointment of senior management, according to the announ
-
Amgen, Johnson & Johnson and Sanofi may bid on the same stage! BI, AstraZeneca, Biogen, Hehuang, Hua Ling and other pharmaceutical companies personnel changes!
Time of Update: 2022-12-30
1. The heads of the four major sectors of AstraZeneca China "arrived" On November 23, Guan Dongmei officially became the new vice president and head of the cardiovascular, renal and metabolic business unit of AstraZeneca China, and reported directly to Lai Minglong, general manager of AstraZeneca China, as a member of the China management team.
-
Eli Lilly, Cinda PD-1 product "broke up"? Cinda's exclusive response: friendly negotiation to recover overseas rights and interests
Time of Update: 2022-12-30
It is not difficult to see that although Innovent has recovered the overseas rights and interests of PD1 from Eli Lilly, other cooperation between Cindilimab products and Lilly, such as combination therapy and the exploration and development pipeline of new indications, is still advancing.
-
Jiangsu: Notice on further strengthening the work of ensuring the supply and price of medical supplies
Time of Update: 2022-12-30
On December 17, the Jiangsu Provincial Market Supervision Bureau and the Food and Drug Administration jointly issued the Notice on Further Strengthening the Work of Ensuring the Supply and Stabilizin
-
At the end of the year, financing in the pharmaceutical field was frequent, and the pharmaceutical company completed a B+ round of financing of more than 100 million yuan
Time of Update: 2022-12-30
According to the data, Huaxian Pharmaceutical is a one-stop CRO & CDMO service platform enterprise, and the company relies on the core technologies in chiral synthesis, biological enzyme catalysis and continuous flow microchannels to develop high-difficulty characteristic APIs and intermediates in the fields of anti-tumor, antiviral and anti-respiratory diseases.
-
Recently, the sales of some drugs have soared, and pharmaceutical glass companies have attracted the attention of investors
Time of Update: 2022-12-30
Recently, with the liberalization of policies and the issuance of home health guidelines by the National Health Commission, the sales of vaccines, traditional Chinese medicines, and analgesic and ant
-
mRNA vaccine second half: Moderna has switched to cancer treatment, clinically reducing the risk of recurrence and death by 44%.
Time of Update: 2022-12-30
On October 12, 2022, Merck and Moderna signed a $250 million partnership agreement for the joint development and commercialization of the Personalized Cancer Vaccine (PCV) mRNA-4157/V940 。 On December 13, Moderna's official website announced that the combination of personalized cancer vaccine mRNA-4157/V940 and PD-1 inhibitor Keytruda showed that compared with Keytruda monotherapy, it can significantly reduce the risk of recurrence or death in stage III and IV melanoma patients after complete tumor resection by 44%!
-
The market of more than 30 billion antithrombotic drugs is highly competitive, and 3 first generic drugs have been added during the year
Time of Update: 2022-12-30
These two products are antithrombotic drugs, of which clopidogrel aspirin tablets are the first imitation, and the sales scale of rivaroxaban tablets in China's three major terminal markets in 2021 exceeded 5 billion yuan.
-
10 domestic new crown epidemic seedlings data revealed, who can "kerong"?
Time of Update: 2022-12-30
According to the company's Phase 3 clinical data published in The Lancet in January 2022, Kwesha targeted the original strain:After 14 days of vaccination, the overall effective rate was 63.
-
7 listed companies expect net profit to double in 2022! 2. For pharmaceutical enterprises
Time of Update: 2022-12-30
According to the statistics of the Oriental Wealth Network Data Center, as of December 19, more than 60 listed companies have disclosed their 2022 annual performance forecasts, and the overall view i
-
【Q&A】SPI product questions and answers
Time of Update: 2022-12-30
Answer: It is recommended to use mannitol Mannogem®XL Opal and XL Ruby, which have high compressibility, high drug load, fast disintegration, low brittleness, good taste, can press out tablets with qualified hardness under various pressures, the dosage is smaller, and the cost is reduced.
-
How innovative drugs extend the golden years
Time of Update: 2022-12-30
Follow-up commercialization is difficult Analysis of the seven years of innovative drug development practice of Chinese pharmaceutical companies, especially innovative pharmaceutical companies, from 2016 to 2022 shows that commercialization, including internationalization, is still being explored, mainly reflected in insufficient preparation, lagging commercialization starting point and insufficient experience in the marketization of original innovative drugs.
